Inotuzumab Ozogamicin

5 trials 4 recruiting LOncology Orphan designation

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

4 Recruiting

0 Completed trials

5 Sponsors

21 Countries

Phase III

Phase II/III

Phase II

Phase I/II

Phase III: 1 Phase II/III: 1 Phase II: 2 Phase I/II: 1

Oversight events:

3 serious breaches 1 corrective measure across 2 trials

View oversight register →

Sponsors using this IMP

Charite Universitaetsmedizin Berlin KöR 1 Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) 1 Fondazione Gimema Franco Mandelli Onlus 1 Karolinska University Hospital 1 Pfizer Inc. 1

All trials

5 total

IntReALL BCP 2020 – International Study for Treatment of Childhood Relapsed Precursor B-cell ALL 2020 Pending

2023-509392-17-00 Phase III 11 countries Charite Universitaetsmedizin Berlin KöR
A Ph2 Superiority Study with InO Monotherapy vs ALLR3 for Induction Treatment of Childhood HR ALL Recruiting

2023-509810-13-00 Phase II 16 countries Pfizer Inc.
Inotuzumab ozogamicin for Acute Lymphoblastic Leukemia Recruiting

2023-504694-20-00 Phase I/II 13 countries Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia Recruiting

2022-501050-11-01 Phase II/III 14 countries Karolinska University Hospital
Trial aimed at examinate the functionality and effectiveness of the drug "IO" in adult patients with a rare form of cancer that affect the c… Recruiting

2023-510516-39-00 Phase II 1 country Fondazione Gimema Franco Mandelli Onlus

Showing 1–5 of 5 trials

← All drugs A–Z